Refreshing results…
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
UploadAuthor Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
Download from www.nature.comTSC2 regulates tumor susceptibility to TRAIL‐mediated T‐cell killing by orchestrating mTOR signaling
Download from onlinelibrary.wiley.comReversal of pre-existing NGFR-driven tumor and immune therapy resistance
Download from www.nature.comMissing publications? Search for publications with a matching author name.